Inspire Medical Systems, Inc. (INSP)
USD 186.97
(-1.96%)
USD 186.97
(-1.96%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -40.27 Million USD | 15.38% |
| 2022 | -47.59 Million USD | -19.43% |
| 2021 | -39.85 Million USD | 29.1% |
| 2020 | -56.2 Million USD | -61.07% |
| 2019 | -34.89 Million USD | -71.25% |
| 2018 | -20.37 Million USD | -27.34% |
| 2017 | -16 Million USD | 7.25% |
| 2016 | -17.25 Million USD | 12.85% |
| 2015 | -19.79 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -15.21 Million USD | -263.69% |
| 2024 Q2 | 5.09 Million USD | 133.51% |
| 2024 Q3 | 14.31 Million USD | 180.8% |
| 2023 FY | -40.27 Million USD | 15.38% |
| 2023 Q3 | -13.47 Million USD | 18.84% |
| 2023 Q2 | -16.59 Million USD | 14.87% |
| 2023 Q1 | -19.49 Million USD | -820.55% |
| 2023 Q4 | 9.29 Million USD | 169.01% |
| 2022 Q4 | 2.7 Million USD | 115.74% |
| 2022 Q2 | -14 Million USD | 12.76% |
| 2022 Q1 | -16.05 Million USD | -781.71% |
| 2022 FY | -47.59 Million USD | -19.43% |
| 2022 Q3 | -17.19 Million USD | -22.75% |
| 2021 Q3 | -9.79 Million USD | 21.91% |
| 2021 FY | -39.85 Million USD | 29.1% |
| 2021 Q1 | -15.68 Million USD | -122.16% |
| 2021 Q2 | -12.54 Million USD | 20.05% |
| 2021 Q4 | -1.82 Million USD | 81.41% |
| 2020 FY | -56.2 Million USD | -61.07% |
| 2020 Q1 | -16.44 Million USD | -76.91% |
| 2020 Q2 | -22.81 Million USD | -38.77% |
| 2020 Q3 | -9.89 Million USD | 56.64% |
| 2020 Q4 | -7.06 Million USD | 28.61% |
| 2019 Q3 | -8.65 Million USD | -5.81% |
| 2019 FY | -34.89 Million USD | -71.25% |
| 2019 Q1 | -8.77 Million USD | -79.23% |
| 2019 Q4 | -9.29 Million USD | -7.42% |
| 2019 Q2 | -8.17 Million USD | 6.85% |
| 2018 Q1 | -5.19 Million USD | -35.08% |
| 2018 Q2 | -5.63 Million USD | -8.51% |
| 2018 Q3 | -4.64 Million USD | 17.53% |
| 2018 Q4 | -4.89 Million USD | -5.33% |
| 2018 FY | -20.37 Million USD | -27.34% |
| 2017 Q1 | -4.12 Million USD | 0.0% |
| 2017 FY | -16 Million USD | 7.25% |
| 2017 Q2 | -4.38 Million USD | -6.3% |
| 2017 Q3 | -3.64 Million USD | 16.77% |
| 2017 Q4 | -3.84 Million USD | -5.4% |
| 2016 FY | -17.25 Million USD | 12.85% |
| 2015 FY | -19.79 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott Laboratories | 6.47 Billion USD | 100.622% |
| Allurion Technologies Inc. | -78.07 Million USD | 48.422% |
| Artivion, Inc. | 5.74 Million USD | 801.341% |
| Avanos Medical, Inc. | 4.2 Million USD | 1058.833% |
| Butterfly Network, Inc. | -145.61 Million USD | 72.343% |
| Butterfly Network, Inc. | -145.61 Million USD | 72.343% |
| Bio-Rad Laboratories, Inc. | 383.79 Million USD | 110.493% |
| Boston Scientific Corporation | 2.34 Billion USD | 101.719% |
| Perspective Therapeutics, Inc. | -15.18 Million USD | -165.255% |
| CONMED Corporation | 130.78 Million USD | 130.792% |
| Edwards Lifesciences Corporation | 1.53 Billion USD | 102.625% |
| Paragon 28, Inc. | -37.3 Million USD | -7.939% |
| Glaukos Corporation | -128.7 Million USD | 68.709% |
| Globus Medical, Inc. | 133.14 Million USD | 130.247% |
| Integer Holdings Corporation | 167.33 Million USD | 124.067% |
| Medtronic plc | 5.14 Billion USD | 100.783% |
| Nevro Corp. | -99.3 Million USD | 59.448% |
| Owlet, Inc. | -28.63 Million USD | -40.65% |
| Penumbra, Inc. | 73.55 Million USD | 154.752% |
| Vicarious Surgical Inc. | -80.66 Million USD | 50.077% |
| Smith & Nephew plc | 425 Million USD | 109.476% |
| Sonendo, Inc. | -57.74 Million USD | 30.258% |
| STERIS plc | 836.11 Million USD | 104.816% |
| Stryker Corporation | 3.88 Billion USD | 101.036% |
| Vapotherm, Inc. | -39.08 Million USD | -3.048% |
| Zimmer Biomet Holdings, Inc. | 1.27 Billion USD | 103.152% |